A preclinical study conducted in human medullary thyroid carcinoma cell lines demonstrated that adefovir dipivoxil, a drug already approved for the treatment of chronic hepatitis B, inhibited RET gene transcription, reducing the expression of endogenous RET proteins [113]. The gene discussed is RET; the disease is chronic hepatitis B virus infection.